A Phase 3 interventional study of Abatacept in Juvenile Idiopathic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 13 sites in Japan. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-26.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Juvenile with a site in Japan — 3 open to participants now, 6 under way, 5 of them phase 3. Arthritis, Juvenile · Japan.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2013, is one of 10 in phase 3, and was the 3rd registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →3 of the 12 studies in Arthritis, Juvenile with a site in Japan are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Japan, United States, Argentina and 15 more countries
Ages 3+
AbbVie · Sites in Japan, United States, Argentina and 14 more countries
Ages 1–17
Eli Lilly and Company · Sites in Japan, Argentina, Australia and 17 more countries
Ages 1–18
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 58 across the 11 interventional studies, 113 across the 1 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 8 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 6 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of Abatacept after intravenous administration in Japanese children and adolescents with active juvenile idiopathic arthritis who have a history of an inadequate response or intolerance to Methotrexate or biologics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have a history of at least 5 joints with active disease and must have currently active articular disease as defined by:
Exclusion Criteria:
Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study
Drug: Abatacept
Also known as: BMS-188667, ONO-4164
Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16
American College of Rheumatology (ACR) pediatric (PED) 30 response was defined as '≥30% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. JIA core set variables defined as the number of active joints, number of joints with Limit of Motion (LOM), physician's global assessment of disease severity, patient global assessment of overall well being, parent assessment of physical function, and acute phase reactant value. A non-responder imputation was applied.
Time frame: Week 16 (Day 113)
Percentage of Participants Experiencing a American College of Rheumatology Pediatric 50, 70, 90 Response or Inactive Disease at Week 16
ACR PED 50 response is defined as '≥50% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. ACR PED 70 response is defined as '≥70% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. ACR PED 90 response is defined as '≥90% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. Inactive disease status is defined as no active joints, physician's global assessment of disease severity equal or less than 10mm and C-reactive protein (CRP) within normal limits (0.3 mg/dL). A non-responder imputation is applied. mm=millimeter; mg/dL=milligrams/deciliter
Time frame: Week 16 (Day 113)
Median Percentage of Improvement From Baseline in Physical Function as Assessed by the Childhood Health Assessment Questionnaire (CHAQ) Disability Index at Week 16
Physical function was evaluated using the disability section of the Childhood Health Assessment Questionnaire (CHAQ). The questionnaire was derived from the adult HAQ. The disability section assessed physical functions in 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common activities. The questions were evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 =unable to do. Higher scores indicate greater dysfunction. A disability index was calculated as the mean of the 8 functional scales. The percentage of Improvement from baseline was calculated using the following equation: (Baseline value - Post-baseline value) / Baseline value x 100.
Time frame: Week 16 (Day 113)
Number of Participants With Death, Serious Adverse Events (SAEs), Drug-Related SAEs, Discontinuation Due to Drug-Related SAEs, Drug-Related Adverse Events (AEs), and Discontinuation Due to Drug-Related AEs During the Short Term Period
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. SAEs also include hospitalizations for elective surgical procedures. Drug-related=related or missing relationship to study drug. Data includes all events from the date of the first dose of the study drug up to 56 days post the last dose of the study drug in the short-term period or start of the long-term period, whichever occurred first.
Time frame: Day 1 up to 56 days post Week 16 (Day 113); approximately 6 months
Maximum Observed Concentration (Cmax) of Abatacept During the Short Term Period
Cmax was obtained from the serum concentration versus time data after intravenous administration of abatacept. Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113. A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110. ug/mL=micrograms/milliliter
Time frame: 9 time points up to Week 16 (Day 113)
Trough Observed Concentration (Ctrough) of Abatacept During the Short Term Period
Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113. A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110. ug/mL=micrograms/milliliter
Time frame: 9 time points up to Week 16 (Day 113)
Number of Participants With Positive Immunogenicity During the Short Term Period
A positive immunogenicity response for 'Cytotoxic T-lymphocyte antigen (CTLA4), Immunoglobulin (Ig)', 'Ig and/or Junction Region', respectively = (1) missing baseline immunogenicity measurement and positive analytical laboratory reported immunogenicity response post-baseline (2) negative baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline (3) positive baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline with titer value strictly greater than the baseline titer value. Assessment based on assay cutpoint value. Serum samples were collected prior to study medication at Week 0 (Day 1), Week 8 (Day 57), and Week 16 (Day 113) in the short term period. Participants who early discontinued from the study or complete and did not switch to commercial abatacept had a serum sample collected on final visit or early termination visit, 28, 84 and 168 days after the last dose.
Time frame: Day 1 up to Week 16 (Day 113)
23 participants were enrolled and 20 participants were treated. Reason for non-treatment was that 3 participants no longer met study criteria.
| Milestone | Abatacept |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
| Milestone | Abatacept |
|---|---|
| Started | 20 |
| Completed | 16 |
| Not completed | 4 |
| Withdrew: Subject request to discontinue | 1 |
| Withdrew: Lack of efficacy | 3 |
American College of Rheumatology (ACR) pediatric (PED) 30 response was defined as '≥30% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. JIA core set variables defined as the number of active joints, number of joints with Limit of Motion (LOM), physician's global assessment of disease severity, patient global assessment of overall well being, parent assessment of physical function, and acute phase reactant value. A non-responder imputation was applied.
| percentage of participants | Abatacept |
|---|---|
| Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16 | 90.0 (68.3 to 98.8) |
ACR PED 50 response is defined as '≥50% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. ACR PED 70 response is defined as '≥70% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. ACR PED 90 response is defined as '≥90% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. Inactive disease status is defined as no active joints, physician's global assessment of disease severity equal or less than 10mm and C-reactive protein (CRP) within normal limits (0.3 mg/dL). A non-responder imputation is applied. mm=millimeter; mg/dL=milligrams/deciliter
| percentage of participants | Abatacept |
|---|---|
| ACR PED 50 | 75.0 (50.9 to 91.3) |
| ACR PED 70 | 70.0 (45.7 to 88.1) |
| ACR PED 90 | 35.0 (15.4 to 59.2) |
| Inactive Disease | 25.0 (8.7 to 49.1) |
Physical function was evaluated using the disability section of the Childhood Health Assessment Questionnaire (CHAQ). The questionnaire was derived from the adult HAQ. The disability section assessed physical functions in 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common activities. The questions were evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 =unable to do. Higher scores indicate greater dysfunction. A disability index was calculated as the mean of the 8 functional scales. The percentage of Improvement from baseline was calculated using the following equation: (Baseline value - Post-baseline value) / Baseline value x 100.
| percentage of improvement from baseline | Abatacept |
|---|---|
| Median Percentage of Improvement From Baseline in Physical Function as Assessed by the Childhood Health Assessment Questionnaire (CHAQ) Disability Index at Week 16 | 43.18 (0.00 to 100.00) |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. SAEs also include hospitalizations for elective surgical procedures. Drug-related=related or missing relationship to study drug. Data includes all events from the date of the first dose of the study drug up to 56 days post the last dose of the study drug in the short-term period or start of the long-term period, whichever occurred first.
| participants | Abatacept |
|---|---|
| Death | 0 |
| SAEs | 2 |
| Drug-Related SAEs | 1 |
| Discontinuation Due to Drug-Related SAEs | 0 |
| Drug-Related AEs | 5 |
| Discontinuation Due to Drug-Related AEs | 0 |
Cmax was obtained from the serum concentration versus time data after intravenous administration of abatacept. Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113. A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110. ug/mL=micrograms/milliliter
| ug/mL | Abatacept |
|---|---|
| Day 57 | 163.13 ± 26.22 |
| Day 85 | 172.43 ± 23.15 |
| Day 113 | 167.85 ± 18.42 |
Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113. A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110. ug/mL=micrograms/milliliter
| ug/mL | Abatacept |
|---|---|
| Day 15 | 25.50 ± 27.61 |
| Day 29 | 38.64 ± 29.08 |
| Day 57 | 17.24 ± 36.63 |
| Day 85 | 16.79 ± 40.01 |
| Day 113 | 15.56 ± 36.61 |
A positive immunogenicity response for 'Cytotoxic T-lymphocyte antigen (CTLA4), Immunoglobulin (Ig)', 'Ig and/or Junction Region', respectively = (1) missing baseline immunogenicity measurement and positive analytical laboratory reported immunogenicity response post-baseline (2) negative baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline (3) positive baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline with titer value strictly greater than the baseline titer value. Assessment based on assay cutpoint value. Serum samples were collected prior to study medication at Week 0 (Day 1), Week 8 (Day 57), and Week 16 (Day 113) in the short term period. Participants who early discontinued from the study or complete and did not switch to commercial abatacept had a serum sample collected on final visit or early termination visit, 28, 84 and 168 days after the last dose.
| participants | Abatacept |
|---|---|
| Number of Participants With Positive Immunogenicity During the Short Term Period | 0 |
Collected over During the cumulative period which is from the first dose date up to 56 days beyond the last dose of study medication in the LT period for participants entering the LT or up to 56 days beyond the last dose of study medication in the ST period for participants not entering the LT period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV ABATACEPT | — | 6/20 (30%) | 20/20 (100%) |
| Event | IV ABATACEPT |
|---|---|
| JUVENILE IDIOPATHIC ARTHRITISMusculoskeletal and connective tissue disorders | 2/20 |
| ENTEROCOLITIS VIRALInfections and infestations | 1/20 |
| GASTROENTERITISInfections and infestations | 1/20 |
| VARICELLAInfections and infestations | 1/20 |
| VIRAL TONSILLITISInfections and infestations | 1/20 |
| LOWER LIMB FRACTUREInjury, poisoning and procedural complications | 1/20 |
| Event | IV ABATACEPT |
|---|---|
| NASOPHARYNGITISInfections and infestations | 17/20 |
| PHARYNGITISInfections and infestations | 12/20 |
| INFLUENZAInfections and infestations | 10/20 |
| STOMATITISGastrointestinal disorders | 7/20 |
| LIGAMENT SPRAINInjury, poisoning and procedural complications | 7/20 |
| HEADACHENervous system disorders | 7/20 |
| CONTUSIONInjury, poisoning and procedural complications | 6/20 |
| UPPER RESPIRATORY TRACT INFLAMMATIONRespiratory, thoracic and mediastinal disorders | 6/20 |
| DIARRHOEAGastrointestinal disorders | 5/20 |
| SEASONAL ALLERGYImmune system disorders | 5/20 |
All Treated Participants: All participants who received at least one dose of study medication
| Age, Categorical(Participants) | Abatacept |
|---|---|
| <=18 years | 20 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | Abatacept |
|---|---|
| Mean | 10.2 ± 3.24 |
| Sex: Female, Male(Participants) | Abatacept |
|---|---|
| Female | 15 |
| Male | 5 |
| Race/Ethnicity, Customized(Participants) | Abatacept |
|---|---|
| Japanese | 20 |
| Region of Enrollment(Participants) | Abatacept |
|---|---|
| Japan | 20 |
Ran from Aug 2013 to primary completion in Nov 2015, 27 months.
Results were first posted in Jan 2017, 1 year 1 month after primary completion.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept